NOVEL SUBSTITUTED PROPANE-2-OL DERIVATIVES

Abstract: The invention relates to novel substituted propane-2-ol derivatives of formula (I), wherein R<1> represents a C1-10alkyl group, a phenyl group or a phenyl-C1-6alkyl group, and the phenyl moiety of the two latter groups may carry at least one substituent selected from the group consisting of a halogen atom, C1-6alkoxy group, phenyl group, phenoxy group and trifluoromethyl group; R<2> represents a hydrogen atom, a C1-10alkyl group or a phenyl group; R<3> and R<4> represent, independently from each other, a C1-10alkyl or phenyl group; X represents a hydrogen atom, halogen atom or a group of formula (A); and in these formulae Y<1> and Y<2> represent, independently from each other, a -N= atom or a group of the formula -CH=, and optical antipodes and racemates thereof, further to pharmaceutical compositions of fungicidal action, containing such compounds, processes for the preparation of these compounds and compositions, finally to a method of treatment by using these compounds and compositions.

Description: NOVEL SUBSTITUTED PROPANE - 2 -OL DERIVATIVES The invention relates to novel substituted propane-2- ol derivatives, optical antipodes and racemates thereof, fungicidal compositions containing such compounds as well as to processes for preparing such compounds and composi¬ tions. Furthermore, the invention relates to a method of treating diseases caused by fungi, said method comprises administering one or more of the compounds of the present invention in a fungicidally effective amount to a mammal, including men, by using a compound of the invention per se or in the form of a pharmaceutical composition. The compounds of the present invention are character- ized by the formula (I) wherein R 1 represents a Cι_ιo alJζ y 1 group, a phenyl group or a phenyl-C^galky1 group, and the phenyl moiety of the two latter groups may carry at least one sub- stituent selected from the group consisting of a halogen atom, C]__galkoxy group, phenyl group, phenoxy group and trifluoromethyl group,- R 2 represents a hydrogen atom, a C 1 _ 1 oalkyl group or a phenyl group; R 3 and R 4 represent, independently from each other, a 80036-67 MR/JG l-10 alkvl or Pheny 1 group,- represents a hydrogen atom, halogen atom or a group of the formula (A) and in this formulae Y 1 and Y 2 represent, independently from each other, a -N= atom or a group of the formula -CH=. The compounds of the formula (I) carrying different substituents in positions 1 and 3 of the basic propane skeleton may exist in the form of optical antipodes. A 1:1 mixture of the antipodes forms a racemic mixture. If there is no hint to an individual antipode, it is self-evident that all the possible three forms are comprised by a ref¬ erence to a compound of the formula (I) . During the prepa¬ ration process of the compounds of the formula (I) a race¬ mic mixture thereof is formed. From this mixture the individual antipodes can be separated in a manner known per se, e.g. by selective crystallization of a diastereo- meric salt pair formed with an optically active compound and then by deliberalization of the optically active com¬ pound of the formula (I) . GB patent specification No. 2,078,719 A relates to highly effective fungicidal compounds, possessing substan¬ tial plant growth regulating effect, too. These compounds are characterized by formula if R represents an alkyl, cycloalkyl, aryl or aralkyl, all these groups being optionally substituted by one or two halogen(s) , or said aryl or aralkyl groups may carry alk- oxy, phenyl, phenoxy or trifluoromethyl substituents; and γl and Y 2 are as defined above. According to the GB patent specification No. 2,099,818 A 2- (2,4-difluorophenyl) -1,3-bis(l,2,4-triazol-l-yl)prop- ane-2—ol is used as a highly effective human fungicide. It is sold in the form of a human fungicidal pharmaceutical composition under the trade name fluconasole or diflucane. In accordance with the GB patent specification No. 2,078,719 A the propane-2-ol derivatives of the formula (B) can be prepared by reacting a Grignard reagent of the formula R-Mg-halogen with dichloroacetone. A thus-obtained l,3—dichloropropane-2-ol derivative of the formula OH I is reacted with a salt, e.g. sodium salt, of imidazole or triazole, taken in an excess, in the presence of a protic or aprotic solvent, e.g. dimethyl formamide. The reaction can be also carried out with epoxi derivatives being prep- ared in situ through elimination of hydrogen chloride from the corresponding dihalogen compound with a base. The tar¬ get compounds can be prepared by reacting the correspond¬ ing l,3-bisimidazolyl- or 1,3-bis(1,2,4-triazol-l-yl)ace¬ tone with a Grignard reagent of the formula R-Mg-halogen, too. According to a further preparation method a compound of the formula R- is reacted with dimethyloxosulphoniummethylide, then a thus-obtained compound of the formula containing an R substituent in the place of R 1 , is reacted, similarly to the process described above, with the sodium salt of imidazole or triazole. The starting materials of the above processes can be prepared by known methods. The process for the preparation of the active ingredi- ent of fluconasole according to GB patent specification No. 2,099,818 A comprises the reaction of compounds of the formula (V) and compounds of the formula (IV) containing a substituent R in the place of R 1 , too but instead of 1, 2,4-triazol-l-yl sodium a base and triazole are used as reactants. A common feature of the processes described in the GB patent specifications Nos. 2,078,719 A and 2,099,818 A resides in that when isolating the target compounds the reaction mixture is first diluted with water, then extracted and the product is isolated and purified by known methods like column chromatography or fractioning in vacuo, etc. The yields amount to about 30-50%. In accordance with the GB patent specification No. 2,078,719 A the esters and ethers of the target alcohols can be prepared by reacting the salt of the alcohol, formed with sodium hydride, with a corresponding acylat- ing or alkylating agent. During tests carried out with the active ingredient of fluconasole, used in a high volume in view of its very substantial human fungicidal action of wide spectrum, it was established that said active ingredient has a rela¬ tively weak effect against the very wide-spread pathogenic fungus Candida albicans. Mainly this resistant species causes the disease called "candidiasis" which is quite wide-spread and very difficult to influence. According to our in vitro tests the active ingredient of fluconasole ensures a full inhibition against other Candida species and other pathogenic fungi in a very low dose, i.e. 0.1 to ιo μg/ml; however, in the case of Candida albicans this inhibiting effect occurs only at a dose of 2500 μg/ml. During our research work with the purpose of obtain¬ ing fungicidal agents of increased effect with broader spectrum it was surprisingly recognized that the silyl ether derivatives of the formula (I) possess a surpris¬ ingly high fungicidal action of broad spectrum. This broad spectrum appears mainly in the case of fungus strains infecting humans. For example, the trimethyl silyl ether corresponding to the active ingredient of fluconasole is 15 times more effective against Candida albicans 'than said active ingredient of fluconasole. This increased activity can be established in the case of a very broad spectrum of pathogenic fungi. Thus, the first object of the present invention relates to propane-2-ol derivatives of the formula (I) R3 wherein R 1 represents a Cτ._ιoalkyl group, a phenyl group or a phenyl-C 1 _galky1 group, and the phenyl moiety of the two latter groups may carry at least one sub¬ stituent selected from the group consisting of a halogen atom, C -galko y group, phenyl group, phenoxy group and trifluoromethyl group,- R2 represents a hydrogen atom, a Cι_ιoalkyl group or a phenyl group,- R 3 and R 4 represent, independently from each other, a Cι_ιoalkyl or phenyl group,- X represents a hydrogen atom, halogen atom or a group of the formula (A) and in this formulae Y 1 and Y 2 represent, independently from each other, a -N= atom or a group of the formula -CH=, and optical antipodes and racemates thereof. Further, it was recognized that the propane-2-ol derivatives of the formula (I) can be prepared through the addition of a silyl triazole or silyl imidazole derivative of the formula wherein Y 1 , R 2 , R 3 and R 4 are as defined above, to an epoxide derivative of the formula wherein X and R 1 are as defined above, or wherein Y 2 and R 1 are as defined above, in the presence of a strongly basic catalyst. Thus, the second object of the present invention is a process for the preparation of the propane-2-ol deriva- tives of the formula (I) and optical antipodes' and race- mates thereof. This process is characterized by a) reacting an epoxi derivative of the formula (II) , wherein X and R 1 are as defined above, with a silyl derivative of the formula (III), wherein R 2 , R 3 , R 4 and Y 1 are as defined above, in the presence of a strong base,- or b) reacting an epoxi derivative of the formula (IV) , wherein Y 2 and R 1 are as defined above, with a silyl derivative of the formula (III), wherein R 2 , R 3 , R 4 and Y 1 are as defined above, in the presence of a strong base to obtain compounds of the formula (I) containing a group of the formula (A) as X; and, if desired, resolving a compound of the formula (I) obtained in the form of a racemate. The additions according to processes a) and b) pro¬ ceed, irrespectively from the meanings of R 1 , R 2 , R 3 , R 4 , X, Y 1 and Y 2 , quickly and with a very good (65 to 85%) efficiency. The reactions are performed in an aprotic medium, pre- ferably aprotic dipolar medium, e.g. dimethyl formamide. As a catalyst strong bases like potassium carbonate or potassium tert-butylate, or an alkali metal salt of tri¬ azole or imidazole, can be used. According to process a) it is possible that only the epoxide group of a compound of the formula (II) is brought into reaction with a silyl derivative of the formula (III) , while the halogen atom in the place of X remains unchanged. In this case only 0.01 to 0.1 mole% of a strong base is used in addition to the excess of the silyl derivative of the formula (III) , and the reaction is per¬ formed at lower (50 to 70°C) temperatures. In such a manner a target compound of the formula (I) containing a chloro atom as X can be very efficiently prepared. Should the halogen atom in the place of X in the starting materials of the formula (II) be replaced by a triazolyl or imidazolyl group, a compound of the formula wherein Z represents an alkali metal, preferably sodium or potassium, and the meaning of Y is identical to that of Y 1 and Y 2 as defined before, containing a heteroaromatic group corresponding to that to be introduced to the place of X, is used as a strong base in a molar amount of 1.01 to 1.10. According to process b) it is also possible that only the epoxide group of a compound of the formula (IV) is brought into reaction by using a corresponding silyl derivative of the formula (III) in an amount corresponding at least to the equimolar amount, suitably in an excess of 10 to 100%, in the presence of 0.01 to 0.10 mole% of a strong base. By appropriately selecting the starting materials of the formulae (II), (III), (IV) and (VII) and the reactants one can prepare substituted propane-2-ol derivatives of the formula (I) containing two identical or different heteroaromatic groups. The compounds of the formulae (II) and (IV) used as starting materials are either known from the GB patent specification No. 2.099,818 A or can be prepared by well- known methods. For example, epoxi derivatives of the for- mula (II) containing a hydrogen atom as X can be prepared by reacting a Grignard reagent of the formula R 1 -Mg-halo- gen with chloroacetone in analogous manner to the process carried out with dichloroacetone and treating the obtained product with a base. When subjecting the silyl ether bond of the substi¬ tuted propane-2-ol derivatives of the formula (I) to stability examinations it was stated they are practically stable in the presence of water (in aqueous solution) in a pH range of 3 to 8, i.e. a range corresponding to that of the human organism. After a storage of 50 hours at room temperature less than 10% of the amount of a compound of the invention decomposes through hydrolysis. In contrast, the esters and ethers disclosed in the GB patent specification 2,078,719 A suffer hydrolysis in the presence of water with a speed higher with orders of magnitude. The fungicidal action of the compounds of the formula (I) was examined in the following in vitro tests. Densitometric measurement of the propagation of yeast fungi A microbiological analysator called BIOSCREEN C (LAB- SYSTEMS, Helsinki, Finland) was used to the measurements. From the- test compounds first a stock solution of a con¬ centration of 50 mg/ml, then in 15 steps a bisecting dilu¬ tion series was prepared with dimethyl sulfoxide. From every dilution step 10 μl each was introduced into the cells of the analysator. Then 390 μl of an aqueous nut- rient solution was pipetted into the cells. In the mix¬ tures obtained the cells of the yeasts, e.g. Candida albi¬ cans, were suspended in such an amount that the optical density of the suspension obtained be about 0,1. Young cultures, shaken at 30°C for about 12 hours, were used to the preparation of the suspensions. The composition of the aqueous nutrient solution was as follows: 1 5 by weight of glucose, 0.5% by weight of yeast extract (a product of the firm OXOID Ltd, Great Britain, under the catalogue No. L21) and 0.5% by weight of nutrient broth (a product of the firm OXOID Ltd, Great Britain, under the catalogue No. CM 1/2) . The concentration of the compounds to be tested in the cells corresponded to 1250, 625, 312, 156, 78, 39, 19, 9, 4, 2, 1, 0.6, 0.3, 0.15 and 0.07 μg/ml, resp. The densitometric measurement of the cultures was carried out during an incubation at 37°C for 30 hours. The change in the turbidity of the culture, which can be followed through optical measurement, is proportional to the propa¬ gation of the yeast fungi. As the minimal inhibitory concentration (MIC) of this test that minimal concentration of the tested compound was determined which was able to prevent totally the propaga¬ tion of the fungus. The obtained results are given in the following Table. Table MIC values [μg/ml] of the individual tests Active agent Candida albicans compound of Example 1 150 compound of Example 3 150 compound of Example 5 9 compound of Example 6 150 compound of Example 8 19 fluconasole 2500 Thus, the third object of the present invention is a method of treating fungicidal infections of mammals, including men. This method is characterized by administer¬ ing a fungicidally effective amount of one or more of the novel propane-2-ol derivatives of the formula (I) or an optical antipode or racemate thereof to said mammal, optionally together with a pharmaceutically acceptable carrier and/or other adjuvant. The therapeutic use of the compounds of the formula (I) is suitable in the case of all the diseases where the main aim is the control of a pathogenic fungus being already present in the organism. The compounds of the pre¬ sent invention can be used both in the human and veteri¬ nary therapies. During such therapies the daily oral or parenteral dose of the compounds of the formula (I) is about 0.1 to 10 mg/kg, by administering said dose at once or in divided subdoses. The fourth object of the present invention relates to pharmaceutical compositions of fungicidal action. These compositions are characterized by containing a fungici¬ dally effective amount of one or more of the compounds of the formula (I) or an optical antipode or racemate, together with a pharmaceutically acceptable carrier and/or other adjuvant. These pharmaceutical compositions are prepared by known methods and are suitable for parenteral or enteral use. The carriers may be non-toxic inert solid or liquid carriers like water, gelatine, milk sugar, starch, pec- tine, magnesium stearate, talc and vegetal oils. These pharmaceutical compositions can be prepared in the usual forms, mainly in solid forms, like rounded-off or angular tablets, dragees, capsules (e.g. gelatine cap¬ sules), pilules and suppositories. Based on one tablet the amount of the solid active agent may vary in a wide range, preferably between 25 mg and 1 g. In addition to the carriers these pharmaceutical compositions may contain usual pharmaceutical additives like preservatives. The pharmaceutical compositions of the invention can be prepared by known methods, like in the case of solid compositions through sieving, mixing, granulating and optionally pressing the components. The thus-obtained com¬ positions may be subjected to usual pharmaceutical post- treatments like to sterilization in the case of injec¬ tions. The present invention is elucidated by the aid of the following non-limiting examples. Example 1. 2- (2,4-Difluorophenyl) -1, 3-bis (1, 2 , 4-triazol-l-yl) -2- (trimethylsilyloxy) propane Under nitrogen atmosphere 11.85 g (0.05 moles) of 1,2- -epoxi-2- (2, 4 -di fluorophenyl) -3- (1, 2, 4-triazol-l-yl) pro¬ pane (prepared in accordance with the process described in GB patent specification No. 2,099,818 A) are reacted with 9.16 g (0.065 moles) of 1- (trimethylsilyl) -1,2,4-triazole and 0.01 g (0.12 mmoles) of 1,2,4-triazol-l-yl sodium in 100 ml of dimethyl formamide for 1 hour at 80°C. The reac¬ tion mixture is cooled to room temperature, neutralized with glacial acetic acid and mixed to 500 ml of water. The aqueous mixture is extracted twice with 100 ml of di- chloromethane each. The combined extracts are washed three times with 100 ml of water each, dried over water-free sodium sulphate and evaporated to solvent-free in vacuo. The evaporation residue is crystallized from 60 ml of n- hexane containing 5% by volume of ethyl acetate. 16.065 g (85%) of the title compound are obtained; m.p.: 69-71°C. Example 2 2- (2,4-Difluorophenyl) -1,3-bis (1,2,4-triazol-l-yl) -2- (trimethylsilyloxy) -propane Under nitrogen atmosphere 10.3 g (0.05 moles) of 1,2- -epoxi-3-chloro-2- (2,4-difluorophenyl)propane are reacted with 14.1 g (0.1 mole) of 1- (trimethylsilyl) -1,2,4-tri¬ azole and 4.78 g (0.0525 moles) of 1,2,4-triazol-l-yl sodium in 100 ml of dimethyl formamide for 1.5 hours at 100°C. The reaction mixture is then diluted with 600 ml of water and the aqueous mixture is extracted three times with 100 ml of dichloromethane each. The combined extracts are washed three times with 100 ml of water each, dried over water-free sodium sulphate and evaporated to solvent- free in vacuo. The evaporation residue is crystallized from 50 ml of ethyl acetate. 13.42 g (71%) of the title compound are obtained; m.p.: 69-71°C. Example 3 1- (Imidazol-1-yl) -2- (2,4-difluorophenyl) -3- (1,2,4-tri- azol-1-yl) -2- (trimethylsilyloxy)propane 4.74 g (0.02 moles) of 1, 2-epoxi-2- (2,4-difluoro- phenyl) -3- (1,2,4-triazol-1-yl)propane are heated at 80°C for 1 hour in 40 ml of acetonitrile with 3.36 g (0.024 moles) of N- (trimethylsilyl)imidazole and 0.055 g (0.5 mmoles) of potassium tert-butylate. The reaction mixture is then cooled back to room temperature, neutralized with glacial acetic acid and evaporated to solvent-free in vacuo. The evaporation residue is crystallized from 25 ml of 1 : 1 by volume mixture of ethyl acetate and n-hexane. 6.18 g (82%) of the title compound are obtained; m.p.: 87- 89°C. Example 4 2- (2,4-Difluorophenyl) -1, 3-bis(imidazol-l-yl) -2- (tri- methylsilyloxy)propane 10.3 g (0.05 moles) of 1,2-epoxi-2- (2,4-difluoro- phenyl)-3-chloropropane are reacted in 100 ml of dimethyl formamide at 100°C for 1 hour with 4.68 g (0.052 moles) of imidazol-l-yl sodium and 21.0 g (0.15 moles) of N- (tri- methylsilyl)imidazole. The reaction mixture is evaporated to the half of its original volume in vacuo. The evapor¬ ation residue is neutralized with glacial acetic acid and mixed to 250 ml of water. The obtained aqueous mixture is extracted three times with 20 ml of dichloromethane each. The combined extracts are washed twice with 50 ml of water each, dried over water-free sodium sulphate and evaporated in vacuo. The evaporation residue is subjected to column chromatography on a column filled with "Kieselgel 40" (particle size: 70-230 mesh) of the firm Merck by using a 20 : l by volume mixture of ethyl acetate and me'thanol as eluting agent. The fractions proved to be pure by thin layer chromatography are combined and evaporated to sol¬ vent-free. The evaporation residue is crystallized from 60 ml of n-hexane. 13.96 g (73.2%) of the title compound are obtained; m.p.: 134-136°C. Example 5 l-Chloro-2- (2,4-difluorophenyl) -3- (1,2,4-triazol-l- yl) -2- (trimethylsilyloxy)propane 4.11 g (0.02 moles) of 1,2-epoxy-2- (2,4-difluoro- phenyl)-3-chloropropane are reacted with 4.23 g (0.03 moles) of 1-(trimethylsilyl) -1,2,4-triazole and 0.1 g (0.001 mole) of 1,2,4-triazol-l-yl potassium in 50 ml of dimethyl formamide at 50°C for 2 hours. Then the reaction mixture is neutralized by glacial acetic acid, mixed with 250 ml of water at room temperature and extracted twice with 50 ml of dichloromethane each. The combined extracts are washed three times with 50 ml of water each, dried over water-free sodium sulphate and evaporated in vacuo. The residue is subjected to column chromatography by the method of Example 4 above. After crystallization from n- heptane 4.9 g (71.5%) of the title compound are obtained; m.p. : 59-61°C. Example 6 2- (2,4-Difluorophenyl) -3- (1,2,4-triazol-l-yl) -2-(tri- methylsilyloxy)propane 5.13 g (0.03 moles) of 1,2-epoxy-2- (2,4-difluoro- phenyl)-propane are reacted with 6.35 g (0.045 moles) of 1- (trimethylsilyl) -1,2,4-triazole and 0.14 g (0.0015 moles) of 1,2,4-triazol-l-yl sodium in 40 ml of dimethyl formamide at 80°C for 3 hours. Then the reaction mixture is cooled to room temperature, neutralized by glacial acetic acid, mixed with 200 ml of water and extracted twice with 50 ml of dichloromethane each. The combined extracts are washed three times with 50 ml of water each, dried over water-free sodium sulphate and evaporated in vacuo. After carrying out a separation as described in Example 5, removal of the solvent and crystallization from n-heptane 6.0 g (64.5%) of the title compound are obtained; m.p.: 51-53°C. Example 7 2- (2,4-Dichlorophenyl) -1- (1,2,4-triazol-1-yl) -3- (imi- dazol-1-yl) -2- (trimethylsilyloxy) ropane 11.85 g (0.05 moles) of 1, -epoxi-2- (2,4-dichloro- phenyl) -3- (1, 2,4- triazol-1-yl) propane are reacted with 9.8 g (0.07 moles) of N- (trimethylsilyl) imidazole and 0.02 g (0.24 moles) of imidazol-l-yl sodium in 100 ml of dimethyl formamide at 80 °C for 1 hour. Then the reaction mixture is proceeded as disclosed in Example 1. 14.86 g (73.2%) of the title compound are obtained; m.p.: 82-85°C. Example 8 l-Chloro-2- (2,4-difluoropheny? ) -3- (imidazol-l-yl) -2- (trimethylsilyloxy) propane 4.11 g (0.02 moles) of 1, 2-epoxi-3-chloro-2- (2, 4-di- fluorophenyl) propane are reacted with 4.20 g (0.03 moles) of N- (trimethylsilyl) imidazole and 0.09 g (0.001 mole) of imidazol-l-yl sodium in 40 ml of dimethyl formamide at 60°C for 2 hours. Then the reaction mixture is neutralized with glacial acetic acid and evaporated in vacuo . The evaporation residue is mixed to 50 ml of water. The aqueous mixture is extracted with 40 ml of dichloro¬ methane. The title compound is recovered from the extract by the column chromatography disclosed in Example 4. 4.96 g (72%) of the title compound are obtained; m.p.: 88-89 °C. Example 9 2- (2, 4-Difluorophenyl) -3- (imidazol-l-yl) -2- (trimethyl¬ silyloxy) propane 5.00 g (29.2 mmoles) of 1, 2-epoxi-2- ( 2,4 - ' di fluoro¬ phenyl) -propane are reacted with 6.4 g of N- (trimethyl¬ silyl) imidazole and 0.13 g (1.46 mmoles) of imidazol-l-yl sodium in 40 ml of dimethyl formamide at 70°C for 1.5 hours. Then the reaction mixture is cooled back to room temperature, neutralized with glacial acetic acid and evaporated in vacuo . The evaporation residue is mixed to 50 ml of water and the aqueous mixture is extracted with 50 ml of dichloromethane. The title compound is recovered from the extract by the column chromatography disclosed in Example 4. 5.6 g (62%) of the title compound of oily nature are obtained; n 20 D: 1.4935. Example 10 Tablets of a weight of 100 mg, containing 10 mg of active ingredient 50.0 g of active ingredient, 285.0 g of lactose, 100.0 g of potato starch, 2.5 g of sodium dodecyl sulphate, 5.0 g of polyvinylpyrrolidone (Kollidon-K 90 R ) , 50.0 g of microcrystalline cellulose (Avicel R ) and 7.5 g of vegetable oil (Sterotex R ) are compressed in a known manner to tablets of a weight of 100 g by wet granulating and pressing. Each of these tab- lets contains 10 mg of active ingredient. Example 11 Dragees of a weight of 125 mg, containing 10 mg of active ingredient The tablets prepared in accordance with the method of Example 10 are covered in a known manner with a covering comprising sugar and talc. Finally, they are polished with a mixture of beewax and carnaubawax. Example 12 Capsules containing 20 mg of active ingredient 40.0 g of active ingredient, 12.0 g of sodium lauryl sulphate, 102.0 g of lactose, 102.0 g of potato starch, 2.4 g of magnesium stearate, and 1.6 g of colloid silicon dioxide are thoroughly mixed together and the obtained mixture is filled into hard gelatine capsules, containing 20 mg of active ingredient each.

Claims: What we claim is: 1. A novel propane- -ol derivative of the formula (I) wherein R 1 represents a Cι_ιoalkyl group, a phenyl group or a pnenyl-Cι_galkyl group, and the phenyl moiety of the two latter groups may carry at least one sub¬ stituent selected from the group consisting of a halogen atom, Cι_galkoxy group, phenyl group, phenoxy group and trifluoromethyl group; R2 represents a hydrogen atom, a Ci-igalkyl group or a phenyl group,- R 3 and R 4 represent, independently from each other, a c l -10 a l k y 1 or phenyl group,- X represents a hydrogen atom, halogen atom or a group of the formula (A) and in this formulae Y 1 and Y 2 represent, independently from each other, a -N= atom or a group of the formula -CH=, and optical antipodes and racemates thereof. 19 2. 2 - (2,4-Difluorophenyl) -1,3-bis(1,2,4-triazol-l-yl) - 2- (trimethylsilyloxy)propane. 3. 1- (Imidazol-l-yl) -2- (2,4-difluorophenyl) -3- (1,2,4- triazol-1-yl) -2- (trimethylsilyloxy)propane. 4. 2- (2,4-Difluorophenyl) -1,3-bis(imidazol-l-yl) -2- (trimethylsilyloxy)propane. 5. l-Chloro-2- (2,4-difluorophenyl) -3- (1,2,4-triazol-l- yl) -2- (trimethylsilyloxy)propane. 6. l-Chloro-2- (2,4-difluorophenyl) -3- (imidazol-l-yl) - 2- (trimethylsilyloxy)propane. 7. 2- (2,4-Difluorophenyl) -3- (1,2,4-triazol-l-yl) -2- (trimethylsilyloxy)propane. 8. 2- (2,4-Difluorophenyl) -3- (imidazol-l-yl) -2- (tri¬ methylsilyloxy)propane. 9. 2- (2,4-Dichlorophenyl) -1- (1,2,4-triazol-l-yl) -3- (imidazol-l-yl) -2- (trimethylsilyloxy)propane. 10. A pharmaceutical composition of fungicidal action characterized by containing a fungicidally effective amount of one or more of the novel propane-2-ole deriva- tive of the formula (I), wherein R 1 , R 2 , R 3 , R 4 , X, γl and Y 2 are as defined in claim 1, or an optical antipode or racemate thereof, together with a pharmaceutically accept¬ able carrier and/or other adjuvant. 11. A method of treating fungicidal infections of mammals, including men, characterized by administering a fungicidally effective amount of one or more of the novel propane-2-ol derivatives of the formula (I) , wherein R 1 , R , R 3 , R 4 , X, Y 1 and Y 2 are as defined in claim 1, or an optical antipode or racemate thereof to said mammal, alone or in the form of a pharmaceutical composition. 12. A process for the preparation of novel propane-2- ol derivatives of the formula 20 - wherein R 1 represents a C 1 _ιo alk y 1 group, a phenyl group or a phenyl-- _galkyl group, and the phenyl moiety of the two latter groups may carry at least one sub¬ stituent selected from the group consisting of a halogen atom, Cι_galkoxy group, phenyl group, phenoxy group and trifluoromethyl group; R 2 represents a hydrogen atom, a Cι_ιo a lkyl group or a phenyl group; R 3 and R 4 represent, independently from each other, a c l-10 a -L k y-L or phenyl group; x represents a hydrogen atom, halogen atom or a group of the formula (A) and in this formulae Y 1 and Y 2 represent, independently from each other, a -N= atom or a group of the formula -CH=, and optical antipodes and racemates thereof, characterized by a) reacting an epoxi derivative of the formula wherein X and R 1 are as defined above, with a silyl derivative of the formula wherein R 2 , R 3 , R 4 and Y 1 are as defined above, in the presence of a strong base,- or b) reacting an epoxi derivative of the formula wherein Y 2 and R 1 are as defined above, with a silyl derivative of the formula (III), wherein R 2 , R 3 , R 4 and Y 1 are as defined above, in the presence of a strong base to obtain compounds of the formula (I) containing a group of the formula (A) as X; and, if desired, resolving a compound of the formula (I) obtained in the form of a racemate. 13. A process as claimed in claim 12, para a), charac¬ terized by using an alkali metal salt of 1,2,4-triazole or imidazole as a strong base. 14. A process as claimed in claim 12, para a), charac¬ terized by carrying out the reaction in a medium based on dimethyl formamide. 15. A process as claimed in claim 12, para b) , charac¬ terized by using an alkali metal alkoxide as a strong base. 16. A process as claimed in claim 12, para a), charac¬ terized by carrying out the reaction in a medium based on dimethyl formamide. 17. A process for the preparation of pharmaceutical compositions having pharmaceutical action, characterized by admixing one or more of the compounds of the formula (I), wherein R 1 , R 2 , R 3 , R 4 , X, Y 1 and Y 2 are as defined in claim 1, or optical antipodes or racemates thereof to a pharmaceutically acceptable carrier and/or other adjuvant and converting the mixture obtained to a pharmaceutical composition in a known manner.

Inventors: CZIBULA LASZLO, DEUTSCH IDA, FARKAS MARIA, HEGEDUES ISTVAN, KREIDL JANOS, SZANTAY CSABA, SZEGEDI MICHALY, CZIBULA, LASZLO, Deutsch, Ida, FARKAS, MARIA, HEGEDUES, ISTVAN, KREIDL, JANOS, SZANTAY, CSABA, SZEGEDI, MICHALY
Applicants: CZIBULA LASZLO, DEUTSCH IDA, FARKAS MARIA, HEGEDUES ISTVAN, KREIDL JANOS, RICHTER GEDEON VEGYESZET, SZANTAY CSABA, SZEGEDI MICHALY, CZIBULA, LASZLO, Deutsch, Ida, FARKAS, MARIA, HEGEDUES, ISTVAN, KREIDL, JANOS, RICHTER GEDEON VEGYESZETI GYAR RT., SZANTAY, CSABA, SZEGEDI, MICHALY
Application year: 1994
Main classification: C07F7
IPC codes: A61K31, A61P31, C07F7